CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
This article was originally published in RPM Report
Executive Summary
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.
You may also be interested in...
Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives
Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.
FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns
Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.
CMS Coverage Group Changes Management, But Not Priorities
Director of CMS’ Coverage and Analysis Group Louis Jacques will leave the agency in March; his replacement, Deputy Tamara Syrek Jensen, will continue to make Coverage with Evidence Development a top priority.